Montreal biotech investors financing life science companies in 2026

Montreal aims to be a top-5 North American life sciences hub by 2027. These 16 biotech investors are actively writing checks into Quebec drug discovery, medtech, and life sciences startups right now.

Montreal's biotech scene has depth that most founders outside the city don't fully appreciate. McGill, Université de Montréal, and UQAM feed research directly into spinout companies. Montréal InVivo coordinates the cluster. Biotech City - including Moderna's new vaccine facility - is expanding in 2026.

The investor base matches. You have dedicated life sciences funds like Amplitude Ventures, AmorChem, CTI Life Sciences, and Lumira Ventures. You have institutional public co-investors in Investissement Québec and Fonds FTQ. And you have BDC's new $150M Life Sciences Venture Fund, launched April 2026.

What separates Montreal biotech from other Canadian cities is the proximity between academic research and investment capital. AmorChem specifically turns academic research into therapeutics. Versant's Frontier Discovery Engine operates across Toronto and Montreal. That research-to-capital pipeline is unusual.

Before you pitch any of these 16 biotech investors, build an Ellty data room with your pitch, scientific data package, and financial model. Send a unique trackable link per fund. Biotech investors review your preclinical or clinical data before anything else.

What is a Montreal biotech investor?

A Montreal biotech investor backs drug discovery, therapeutic platforms, medical devices, and life sciences infrastructure companies. They're different from generalist VCs - most require scientific diligence capability, milestone-based funding structures, and long time horizons.

Montreal has four dedicated life sciences funds: Amplitude Ventures, AmorChem, CTI Life Sciences, and Lumira Ventures. Most other investors on this list are generalists or public institutions that co-invest in life sciences deals alongside dedicated funds.

The key to Montreal's biotech advantage is the research pipeline. McGill, UdeM, and the clinical network at CHUM, MUHC, and Sainte-Justine generate IP directly into startup formation. AmorChem specifically incubates academic research. If your company came out of Montreal's university system, lead with that research provenance.

For broader context on Quebec investing, see Quebec investors. Read what investors look for in a data room before any biotech investor meeting.

16 Montreal biotech investors

1. Amplitude Ventures

Montreal's precision medicine and AI-bio fund. Amplitude backs companies at the intersection of biology and AI, investing in precision medicine from drug discovery through clinical development. In April 2026, Amplitude led the founding round for RIME Therapeutics. Their 2025 investments include contributions to Congruence Therapeutics' $39.5M round. For Montreal biotech founders with an AI or computational biology angle, Amplitude is your most relevant first call.

• Recent Deals: RIME Therapeutics founding round lead (April 2026); Congruence Therapeutics $39.5M co-investor (2025); 30 companies over 6 years; 3 investments in 2025; CA$200M+ raised
• LinkedIn: Amplitude Ventures LinkedIn
• Sector Focus: Precision medicine, AI-bio, computational biology, oncology, drug discovery
• Stage Focus: Seed, Series A
• Location: Montreal, QC
• Website: amplitudevc.com

2. AmorChem

Montreal's academic spinout specialist. AmorChem turns McGill, UdeM, and other Quebec university research directly into therapeutic companies through incubation and proof-of-concept funding. They write $500K to $3M in early-stage checks specifically for pre-clinical companies that haven't yet proven commercial viability. If your Montreal biotech came out of academic research, AmorChem is the first fund to approach before any institutional VC.

• Recent Deals: Active pre-clinical incubation portfolio from Montreal and Quebec academic institutions; early-stage proof-of-concept investments 2025-2026; multiple Quebec university partnerships
• LinkedIn: AmorChem LinkedIn
• Sector Focus: Therapeutic spinouts, drug discovery, academic biotech
• Stage Focus: Pre-seed, Seed (pre-clinical)
• Location: Montreal, QC
• Website: amorchem.com

3. CTI Life Sciences

Canadian biotech fund with $345M AUM and global reach. CTI backs pre-clinical and clinical stage companies in therapeutics and medical devices. They have a specific interest in Canadian biotech with international development potential. For Montreal therapeutics founders at pre-clinical or Phase I stage, CTI has the scientific expertise and milestone-based funding structure that matches your timeline.

• Recent Deals: Active pre-clinical and clinical stage investments 2025-2026; $345M AUM; Canadian biotech focus with international co-investor network
• LinkedIn: CTI Life Sciences LinkedIn
• Sector Focus: Therapeutics, medical devices, clinical stage biotech
• Stage Focus: Pre-clinical, Clinical
• Location: Montreal, QC
• Website: ctisciences.com

4. Lumira Ventures

Canada's largest life sciences VC with offices in Montreal. Lumira has funded 100+ companies over 20 years and is currently raising $200M USD for Fund V. They co-invested in Congruence Therapeutics alongside Amplitude. Lumira backs biotech, biotherapeutics, and medical devices from early stage through revenue. For Montreal biotech founders at seed through Series B, Lumira's depth of experience and Canadian institutional backing is hard to match.

• Recent Deals: Fund V raising $200M USD + $30M CAD Cancer Breakthrough Fund; Congruence Therapeutics co-investor (2025); 100+ portfolio companies; active Montreal and Canadian life sciences deal flow
• LinkedIn: Lumira Ventures LinkedIn
• Sector Focus: Biotech, biotherapeutics, medical devices, diagnostics
• Stage Focus: Seed to late stage
• Location: Montreal, QC (Toronto and San Francisco offices)
• Website: lumiraventures.com

5. Versant Ventures

Global biotech VC with a Frontier Discovery Engine specifically operating in Montreal and Toronto. Versant has taken 50 companies to IPO and backed Dayra Therapeutics (which emerged from their Montreal-Toronto discovery engine with $70M+ in committed funding including a $50M Biogen collaboration). For Montreal drug discovery founders with strong research credentials, Versant's local discovery infrastructure is the most valuable resource on this list.

• Recent Deals: Dayra Therapeutics $70M+ including $50M Biogen collaboration (2025); active Frontier Discovery Engine in Montreal and Toronto; 50 IPOs in fund history
• LinkedIn: Versant Ventures LinkedIn
• Sector Focus: Biopharma, drug discovery, biotech platforms
• Stage Focus: Seed, Series A (founding-stage companies)
• Location: Montreal, QC / Toronto (Frontier Discovery Engine)
• Website: versantventures.com

6. BDC Life Sciences Venture Fund

BDC launched a dedicated $150M Life Sciences Venture Fund in April 2026 specifically to support Canadian biotech companies. This is a new, actively deploying fund - not a co-investment mandate from BDC's general portfolio. For Montreal biotech founders at seed and Series A, this is fresh capital with a specific life sciences mandate that wasn't available before 2026.

• Recent Deals: $150M Life Sciences Venture Fund launched April 2026; actively deploying into Canadian biotech; specific mandate for next generation of Canadian life sciences companies
• LinkedIn: BDC Capital LinkedIn
• Sector Focus: Canadian life sciences, biotech, medical devices, diagnostics
• Stage Focus: Seed, Series A
• Location: Montreal, QC (national mandate)
• Website: bdc.ca

7. Investissement Québec

Quebec's provincial investment arm has an explicit life sciences mandate and co-invests in biotech with clear Quebec operations. IQ writes $1M to $25M+ checks and is the anchor public co-investor in most major Quebec biotech rounds. Their Quebec Life Sciences Strategy 2025-2028 targets top-5 North American status by 2027. For Montreal biotech founders at Series A and beyond, IQ is a reliable co-investor that follows private leads.

• Recent Deals: Active Quebec life sciences equity and loan programs 2025-2026; Quebec Life Sciences Strategy 2025-2028 public investments; Biotech City and Inspire Bio Innovations support
• LinkedIn: Investissement Québec LinkedIn
• Sector Focus: Quebec biotech, life sciences, all sectors
• Stage Focus: Seed to growth
• Location: Montreal, QC
• Website: investquebec.com

8. Fonds de solidarité FTQ

Quebec's $23B+ labor-sponsored fund co-invests in biotech alongside private VCs. Fonds FTQ deployed $241M in 172 Quebec businesses in 2025-2026 and has a specific life sciences co-investment track record. For biotech founders with Quebec operations, add Fonds FTQ to your co-investor list once a private lead is confirmed.

• Recent Deals: $241M deployed in 172 Quebec businesses (2025-2026); active Quebec life sciences co-investment; $23B+ net assets (November 2025)
• LinkedIn: Fonds de solidarité FTQ LinkedIn
• Sector Focus: Quebec biotech, life sciences, all sectors
• Stage Focus: Seed to growth
• Location: Montreal, QC
• Website: fondsftq.com

9. Teralys Capital

Quebec's fund-of-funds and direct co-investor in life sciences. Teralys manages several billion in assets and backs life sciences VCs as an LP while also co-investing directly. They're the institutional backbone behind several Quebec biotech funds. For Montreal biotech founders looking to bring the full Quebec investment infrastructure into a round, a Teralys LP relationship with your lead fund is a useful signal.

• Recent Deals: Active LP investments in Quebec life sciences funds; direct co-investments in Quebec biotech 2025-2026; institutional anchor for Quebec VC ecosystem
• LinkedIn: Teralys Capital LinkedIn
• Sector Focus: Quebec life sciences, tech, all sectors
• Stage Focus: Fund-of-funds and direct co-investment
• Location: Montreal, QC
• Website: teralyscapital.com

10. Desjardins Capital

Quebec's cooperative financial institution co-invests in Quebec biotech and healthcare companies. Desjardins backed Behaviour Interactive and Vention, and has life sciences investments on its books. For Montreal biotech founders with Quebec operations and a clear commercialization path, Desjardins adds institutional credibility alongside financial capital.

• Recent Deals: Vention $150M CAD co-investor (2025); new investment model launched January 2026; CRCD $116.5M net earnings FY2025; Quebec life sciences network
• LinkedIn: Desjardins Capital LinkedIn
• Sector Focus: Quebec biotech, healthcare, all industries
• Stage Focus: Seed to growth
• Location: Montreal, QC
• Website: desjardins.com

11. Panache Ventures

Canada's most active pre-seed fund occasionally backs biotech tools and AI-bio companies with a clear platform thesis. Panache has a Montreal partner and writes checks up to $1.5M before revenue. For AI-bio or biotech infrastructure founders - not drug development companies - Panache is worth approaching at pre-revenue stage if you have a technical founder with domain expertise.

• Recent Deals: Nord Quantique (Q1 2026, quantum computing for life sciences); Soma Energy (April 2026); 5 investments in 2026; active Montreal deal flow
• LinkedIn: Panache Ventures LinkedIn
• Sector Focus: Biotech tools, AI-bio, healthtech, deep tech, enterprise SaaS
• Stage Focus: Pre-seed, Seed
• Location: Montreal, QC (offices in 4 cities)
• Website: panache.vc

12. Real Ventures

Montreal's foundational VC backs digital health and biotech tools companies at pre-revenue. Real runs FounderFuel and has backed companies with life sciences data platform theses. For biotech software or digital health founders, Real is worth approaching via FounderFuel.

• Recent Deals: Active FounderFuel cohorts 2025-2026; 100+ portfolio companies; $600M+ raised since inception; active digital health deal flow
• LinkedIn: Real Ventures LinkedIn
• Sector Focus: Biotech tools, digital health, SaaS, enterprise
• Stage Focus: Pre-seed, Seed
• Location: Montreal, QC
• Website: realventures.com

13. Inovia Capital

Montreal's leading full-stack VC backs digital health and AI-bio companies alongside its broader portfolio. Inovia co-launched the $138M Venture Scientist Fund with Mila in January 2026, which targets AI research companies including AI-driven drug discovery. For Montreal founders at the intersection of AI and life sciences, Inovia's Venture Scientist Fund is a more relevant entry point than Inovia's main fund.

• Recent Deals: Mila Venture Scientist Fund CAD $138M (January 2026); 15 investments in 2025; US$2.2B+ AUM; AI-bio and digital health portfolio
• LinkedIn: Inovia Capital LinkedIn
• Sector Focus: Digital health, AI-bio, SaaS, fintech, consumer
• Stage Focus: Seed to late stage
• Location: Montreal, QC (global offices)
• Website: inovia.vc

14. Cycle Capital

Montreal's cleantech and sustainability fund backs synthetic biology and sustainable biotech companies at the intersection of biology and climate. For Montreal founders building in industrial biotech, precision fermentation, or sustainable ingredients, Cycle Capital is the most relevant specialist investor in Quebec.

• Recent Deals: Active sustainable biotech and synbio deployment 2025-2026; Montreal-based cleantech and sustainability mandate; alternative protein and fermentation deal flow
• LinkedIn: Cycle Capital LinkedIn
• Sector Focus: Synthetic biology, sustainable biotech, industrial biotech, alternative proteins
• Stage Focus: Seed, Series A
• Location: Montreal, QC
• Website: cyclecapital.com

15. Anges Québec

Canada's largest angel network includes medical doctors, pharma executives, and biotech operators among its 230+ members. For Quebec biotech founders raising $100K-$500K before approaching dedicated life sciences VCs, Anges Québec's structured pitch process and medical/pharma network is worth the time.

• Recent Deals: EmergConnect $1.75M seed (2025); 3 investments in 2025; 230+ members; active Quebec biotech and life sciences deal flow
• LinkedIn: Anges Québec LinkedIn
• Sector Focus: Quebec biotech, life sciences, tech
• Stage Focus: Pre-seed, Seed
• Location: Montreal, QC
• Website: angesquebec.com

16. Export Development Canada

Canada's export credit agency writes equity checks in life sciences companies with cross-border development plans. EDC is underused by biotech founders who don't realize they offer equity alongside debt. For Montreal biotech founders at Series A+ with US clinical trial plans or international licensing discussions, EDC can provide capital and government-backed credibility.

• Recent Deals: Active co-investment across Canadian life sciences companies with export potential; equity and debt instruments for companies targeting US and international markets
• LinkedIn: Export Development Canada LinkedIn
• Sector Focus: Export-ready biotech, life sciences with international plans, medical devices
• Stage Focus: Series A, B
• Location: Ottawa, ON (active Montreal deal flow)
• Website: edc.ca

How Montreal biotech investors evaluate scientific data

Biotech investors review your scientific data package before your financial model - the opposite of software VCs. They want mechanism of action clarity, preclinical efficacy data with appropriate controls, and a realistic assessment of what you don't yet know.

Dead portfolio companies in a fund's biotech portfolio can actually be informative - failed clinical candidates are normal in biotech. What's a red flag is if a fund's portfolio companies went quiet during a funding drought without any scientific progress updates. That indicates portfolio management problems, not just bad luck.

Build your Ellty data room with your scientific data organized in a clear structure - mechanism of action, efficacy data, safety profile, regulatory pathway, and financial projections in that order. Send trackable links so you see which sections investors review first. Read how to organize your data room before any biotech investor meeting.

SR&ED credits and biotech burn rate

Quebec's Scientific Research and Experimental Development credits apply directly to biotech R&D spend. The enhanced 35% ITC threshold jumped to $4.5M in 2025, and R&D labor costs qualify. For a Montreal biotech burning $150K/month on preclinical research, SR&ED can return $50K+/month in refundable credits.

Montreal biotech investors factor SR&ED into burn calculations. A company burning $1.5M annually gross may be burning $1M net after credits. That's 50% more runway at the same capital raise. If you're not modeling SR&ED into your pitch, you're presenting artificially high cash needs.

Set up your Ellty data room with a financial model that shows gross burn vs. net burn after SR&ED credits. Upload alongside your scientific data package and send trackable links. Read what investors look for in a data room before any Montreal biotech investor meeting.

How to get through due diligence in biotech

Biotech due diligence takes longer than software - typically 12-20 weeks from first meeting to term sheet. Investors hire scientific advisors to review your data. They call your academic collaborators. They map your IP to similar compounds in development.

The fastest way to slow down biotech diligence is missing documents. Have your IP assignments, lab notebooks, material transfer agreements, and sponsored research agreements in one organized place before diligence starts.

Set up your Ellty data room with every document organized before any due diligence request comes in. Use Ellty to track which sections investors review and what they skip. If AmorChem's scientific advisor opens your mechanism of action section four times, that's where to focus follow-up. Read due diligence for investors to understand exactly what biotech VCs review.